lipid-a and Hemorrhagic-Fever--Ebola

The 2013-2016 West African Ebola virus (EBOV) disease outbreak was the largest filovirus outbreak to date. Over 28 000 suspected, probable, or confirmed cases have been reported, with a 53% case-fatality rate. The magnitude and international impact of this EBOV outbreak has highlighted the urgent need for a safe and efficient EBOV vaccine. To this end, we demonstrate the immunogenicity and protective efficacy of FILORAB1, a recombinant, bivalent, inactivated rabies virus-based EBOV vaccine, in rhesus and cynomolgus monkeys. Our results demonstrate that the use of the synthetic Toll-like receptor 4 agonist glucopyranosyl lipid A in stable emulsion (GLA-SE) as an adjuvant increased the efficacy of FILORAB1 to 100% protection against lethal EBOV challenge, with no to mild clinical signs of disease. Furthermore, all vaccinated subjects developed protective anti-rabies virus antibody titers. Taken together, these results support further development of FILORAB1/GLA-SE as an effective preexposure EBOV vaccine.

Topics: Adjuvants, Immunologic; Animals; Antibodies, Viral; Ebola Vaccines; Ebolavirus; Emulsions; Female; Glucosides; Hemorrhagic Fever, Ebola; Lipid A; Macaca fascicularis; Macaca mulatta; Male; Rabies; Rabies Vaccines; Rabies virus; Toll-Like Receptor 4; Vaccines, Inactivated; Vaccines, Synthetic